Hospital
Mcleod Medical Center-Dillon
Mcleod Medical Center-Dillon was paid $13.63M by Medicaid between Jan 2018 and Dec 2024, across 193 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 13% of everything it billed.
33Billing provider infoMCLEOD MEDICAL CENTER-DILLON
DILLON, SC 29536
DILLON, SC 29536
33aNPI1598746141assigned 11/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.63M
24GClaims592,032
24DCodes billed193
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#24 of 115
Median peer was paid$2.47M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ERVIN, SAMUEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,311 | $1.72M | |
| 2019 | 88,626 | $1.66M | |
| 2020 | 77,852 | $1.33M | |
| 2021 | 89,058 | $1.75M | |
| 2022 | 93,704 | $2.29M | |
| 2023 | 82,975 | $2.54M | |
| 2024incomplete | 74,506 | $2.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 13% | 35,226 | 27,118 | $1.83M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 29,887 | 26,795 | $1.64M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 11% | 10,169 | 9,315 | $1.43M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 29,874 | 26,122 | $1.23M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.6% | 3,627 | 3,405 | $628K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.3% | 5,337 | 1,862 | $450K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.0% | 3,900 | 3,655 | $406K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.0% | 10,537 | 8,594 | $404K |
| 81001 | 2.7% | 16,256 | 14,501 | $371K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 4,307 | 4,049 | $332K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 3,396 | 3,145 | $316K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 10,903 | 2,392 | $273K |
181 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 4,354 | $261K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.9% | 6,912 | $257K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.7% | 13,331 | $233K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.5% | 1,424 | $210K |
| 59025 | Fetal non-stress test | 1.5% | 3,291 | $208K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.5% | 2,751 | $203K |
| 80053 | Comprehensive metabolic panel | 1.3% | 22,444 | $180K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 10,263 | $159K |
| 87070 | 1.2% | 2,572 | $159K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 6,366 | $138K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,258 | $127K |
| 76830 | Ultrasound, transvaginal | <1% | 1,369 | $127K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,390 | $119K |
| 76801 | <1% | 2,101 | $114K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,147 | $109K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 5,528 | $104K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,417 | $99K |
| 81003 | <1% | 4,473 | $93K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,980 | $87K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 307 | $84K |
| 81025 | <1% | 9,433 | $71K | |
| 99285 | Emergency room visit (most serious) | <1% | 11,656 | $70K |
| 73130 | <1% | 1,134 | $65K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,096 | $60K |
| 73630 | <1% | 1,311 | $58K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,218 | $56K |
| 87210 | <1% | 1,452 | $55K | |
| 73564 | <1% | 1,564 | $53K | |
| 73610 | <1% | 1,093 | $52K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,567 | $47K |
| 73030 | <1% | 877 | $37K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,419 | $37K |
| 36416 | <1% | 3,564 | $33K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,013 | $32K |
| 96376 | <1% | 2,831 | $30K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 559 | $30K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 210 | $30K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 281 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,767 | $28K |
| 74018 | <1% | 976 | $24K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,551 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,227 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,311 | $17K |
| 73110 | <1% | 324 | $17K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 154 | $12K |
| 82948 | <1% | 2,046 | $12K | |
| 87077 | <1% | 1,334 | $11K | |
| 74022 | <1% | 795 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,010 | $11K |
| G0378 | Hospital observation service, per hour | <1% | 3,495 | $11K |
| 87430 | <1% | 2,369 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,632 | $10K |
| 97161 | <1% | 1,456 | $9K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,339 | $8K |
| 72100 | <1% | 350 | $8K | |
| 85610 | <1% | 10,958 | $8K | |
| 84702 | <1% | 2,098 | $8K | |
| 87807 | <1% | 1,737 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,276 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,461 | $7K |
| 97014 | <1% | 132 | $7K | |
| 86850 | <1% | 1,050 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 167 | $7K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 999 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,694 | $6K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,694 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 210 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,387 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,236 | $4K |
| 71250 | <1% | 63 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 310 | $4K |
| 85027 | <1% | 7,090 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,305 | $3K |
| 73502 | <1% | 97 | $3K | |
| 73090 | <1% | 70 | $3K | |
| 83735 | <1% | 15,403 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,806 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 205 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 186 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,796 | $2K |
| 73590 | <1% | 42 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,243 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,497 | $2K |
| 84484 | <1% | 12,496 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,266 | $2K |
| 73080 | <1% | 37 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,405 | $2K |
| 82803 | <1% | 1,816 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 501 | $1K |
| 36600 | <1% | 1,262 | $1K | |
| 83655 | <1% | 488 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,554 | $1K |
| J3490 | Unclassified drugs | <1% | 1,177 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,889 | $1K |
| 92523 | <1% | 67 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 368 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 75 | $1K |
| 83690 | <1% | 8,370 | $965.77 | |
| 93971 | <1% | 15 | $861.07 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,451 | $789.75 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 155 | $742.02 |
| 80061 | Lipid panel | <1% | 882 | $711.88 |
| 87040 | <1% | 6,157 | $696.89 | |
| 83013 | <1% | 12 | $688.39 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 552 | $663.31 |
| 70486 | <1% | 53 | $567.15 | |
| A9270 | Non-covered item or service | <1% | 2,801 | $556.10 |
| 85730 | <1% | 8,434 | $512.36 | |
| 83880 | <1% | 4,237 | $505.22 | |
| 76642 | <1% | 12 | $491.04 | |
| 80076 | <1% | 2,181 | $450.04 | |
| 72040 | <1% | 14 | $417.96 | |
| 86738 | <1% | 167 | $387.90 | |
| 83605 | <1% | 4,660 | $384.41 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 108 | $370.09 |
| 84100 | <1% | 1,372 | $355.47 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,599 | $351.33 |
| J1815 | Injection, insulin, per 5 units | <1% | 59 | $337.79 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,999 | $271.74 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 120 | $202.27 |
| 82550 | <1% | 614 | $137.25 | |
| 87147 | <1% | 441 | $133.45 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 519 | $127.76 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,692 | $126.56 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,017 | $126.47 |
| 85014 | <1% | 472 | $121.22 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 697 | $117.08 |
| 85379 | <1% | 1,179 | $108.87 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 70 | $98.43 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,095 | $98.24 |
| 94644 | <1% | 1,084 | $64.99 | |
| 80320 | <1% | 339 | $62.06 | |
| 84145 | <1% | 1,002 | $60.36 | |
| 87186 | <1% | 1,828 | $55.00 | |
| 73552 | <1% | 14 | $39.14 | |
| 84703 | <1% | 60 | $29.22 | |
| 86901 | <1% | 1,993 | $25.22 | |
| 86900 | <1% | 1,994 | $25.22 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,906 | $18.28 |
| 87205 | <1% | 359 | $18.27 | |
| 82077 | <1% | 1,474 | $15.32 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 962 | $13.30 |
| 82570 | <1% | 12 | $11.97 | |
| 87140 | <1% | 67 | $9.00 | |
| 82565 | <1% | 44 | $4.48 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,316 | $2.43 |
| 80143 | <1% | 403 | $1.75 | |
| 84439 | <1% | 453 | $1.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 64 | $0.24 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 93 | $0.00 |
| 86140 | 0% | 53 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 402 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 28 | $0.00 |
| 85651 | 0% | 377 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 115 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 164 | $0.00 |
| 97162 | 0% | 26 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 364 | $0.00 |
| 85018 | 0% | 512 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 111 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 12 | $0.00 |
| 80177 | 0% | 12 | $0.00 | |
| 83550 | 0% | 25 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| 82728 | 0% | 15 | $0.00 | |
| 94762 | 0% | 44 | $0.00 | |
| 94760 | 0% | 18 | $0.00 | |
| 80179 | 0% | 274 | $0.00 | |
| 90715 | 0% | 224 | $0.00 | |
| 84481 | 0% | 210 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 18 | $0.00 |
| 83540 | 0% | 26 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 43 | $0.00 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 0% | 38 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 26 | $0.00 |
| 86003 | 0% | 19 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 13 | $0.00 |
| 90714 | 0% | 13 | $0.00 | |
| 82140 | 0% | 14 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERVIN, SAMUEL (SR VP AND CFO)
Parent organizationMCLEOD HEALTH
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.